Robert Princenthal, MD, presented “Transurethral Ultrasound Ablation (TULSA)” during the virtual 5th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer in September 2021.

How to cite: Princenthal, Robert. Practical Applications and Clinical Utility of PYLARIFY Injection: Implications for Urology and Radiation Oncology.” September 2021. Accessed Aug 2022.

Practical Applications and Clinical Utility of PYLARIFY Injection: Implications for Urology and Radiation Oncology – Summary

In this presentation, supported by Profound Medical, Robert Princenthal, MD, a board-certified radiologist serving as the medical director for RadNet’s Prostate Imaging Program at the RadNet Imaging Centers, Rolling Oaks Radiology, Thousand Oaks, California, discusses transurethral ultrasound ablation (TULSA), an incision-free, ablative intervention that offers real-time vision. Dr. Princenthal explains TULSA-PRO as inside-out ablation using real-time MRI imaging and thermometry, whereby transurethral heating of the prostate is controlled by a robotic closed-loop temperature control to enable whole-gland ablation of any size prostate. He then illustrates the procedure, including thermal heat maps, noting its precision. In addition to what Dr. Princenthal calls the incredible control and precision that TULSA-PRO offers, he outlines its advantages including predictable outcomes, minimized risk of side effects, and comprehensive applications (for any size prostate, and for whole-gland, hemi-gland, or focal ablation). Dr. Princenthal summarizes a two-year trial, TACT, completed as part of the U.S. Food and Drug Administration (FDA) approval process, highlighting a 95 percent reduction in mean prostate-specific antigen (PSA) two years post-procedure, a demonstrated histological benefit in 80 percent of men at 12-month biopsy, and a rate of only seven percent of patients requiring additional intervention two years post-procedure. He references an FDA guidance document then turns to a description of the process and team approach among urologists and imaging centers. He shares further images demonstrating the procedure’s effectiveness and highlights again its flexibility for various types of patient needs. He shares procedure exclusion criteria before turning to patient outcomes and satisfaction, sharing positive patient feedback. Dr. Princenthal closes by outlining the advantages of the Profound partnership, from clinical training to marketing support and a care registry to track long-term outcomes and sharing resources for patient information.

The Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer brings together key international opinion leaders of every clinical subspecialty involved in patient care. This event is an integral part of the AdMeTech Foundation’s Annual Summit, which was established in 2016 and became seminal in shaping the state of the art and future vision for precision care. The goal of this event is three-fold: 1) Educating the key stakeholders; 2) Supporting a sustained cross-disciplinary dialogue and consensus on the best emerging clinical practices and research priorities; and 3) Expediting clinical adoption of promising novel diagnostics and therapeutics. For more educational activities from this virtual event, visit our collection page.